BOEING CO/THE (BA)

US0970231058 - Common Stock

166.81  +2.48 (+1.51%)

After market: 166.4 -0.41 (-0.25%)

Fundamental Rating

2

BA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 64 industry peers in the Aerospace & Defense industry. BA has a bad profitability rating. Also its financial health evaluation is rather negative. BA is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

BA had negative earnings in the past year.
In the past year BA had a positive cash flow from operations.
BA had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BA reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.62%, BA is in line with its industry, outperforming 42.19% of the companies in the same industry.
Industry RankSector Rank
ROA -1.62%
ROE N/A
ROIC N/A
ROA(3y)-2.75%
ROA(5y)-3.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BA has a worse Gross Margin (9.93%) than 78.13% of its industry peers.
In the last couple of years the Gross Margin of BA has declined.
BA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 9.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-12.55%

1

2. Health

2.1 Basic Checks

BA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BA has been increased compared to 1 year ago.
The number of shares outstanding for BA has been increased compared to 5 years ago.
BA has a better debt/assets ratio than last year.

2.2 Solvency

BA has an Altman-Z score of 1.33. This is a bad value and indicates that BA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.33, BA is doing worse than 62.50% of the companies in the same industry.
The Debt to FCF ratio of BA is 11.80, which is on the high side as it means it would take BA, 11.80 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BA (11.80) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.8
Altman-Z 1.33
ROIC/WACCN/A
WACC8.42%

2.3 Liquidity

BA has a Current Ratio of 1.14. This is a normal value and indicates that BA is financially healthy and should not expect problems in meeting its short term obligations.
BA has a Current ratio of 1.14. This is in the lower half of the industry: BA underperforms 71.88% of its industry peers.
A Quick Ratio of 0.31 indicates that BA may have some problems paying its short term obligations.
The Quick ratio of BA (0.31) is worse than 96.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.31

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.33% over the past year.
Looking at the last year, BA shows a quite strong growth in Revenue. The Revenue has grown by 16.79% in the last year.
The Revenue has been decreasing by -5.11% on average over the past years.
EPS 1Y (TTM)47.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q73.14%
Revenue 1Y (TTM)16.79%
Revenue growth 3Y9.87%
Revenue growth 5Y-5.11%
Revenue growth Q2Q10.2%

3.2 Future

The Earnings Per Share is expected to grow by 36.24% on average over the next years. This is a very strong growth
Based on estimates for the next years, BA will show a quite strong growth in Revenue. The Revenue will grow by 11.24% on average per year.
EPS Next Y96.8%
EPS Next 2Y78.47%
EPS Next 3Y55.79%
EPS Next 5Y36.24%
Revenue Next Year11.77%
Revenue Next 2Y12.76%
Revenue Next 3Y12.1%
Revenue Next 5Y11.24%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BA. In the last year negative earnings were reported.
Also next year BA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BA indicates a slightly more expensive valuation: BA is more expensive than 62.50% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BA is valued cheaply inside the industry as 85.94% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 22.93
EV/EBITDA 128.1

4.3 Compensation for Growth

BA's earnings are expected to grow with 55.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.47%
EPS Next 3Y55.79%

0

5. Dividend

5.1 Amount

BA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BOEING CO/THE

NYSE:BA (4/25/2024, 7:04:00 PM)

After market: 166.4 -0.41 (-0.25%)

166.81

+2.48 (+1.51%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap101.67B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.62%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 9.93%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.14
Quick Ratio 0.31
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)47.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y96.8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.79%
Revenue growth 3Y9.87%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y